VolitionRX (VNRX) Registration Filing summary

Company overview and business model

• Multi-national epigenetics company developing blood tests for early detection and monitoring of diseases like cancer and sepsis using chromosomal structures and transcription factors as biomarkers.

• Product portfolio includes Nu.Q® Vet (cancer screening for dogs), Nu.Q® NETS (detects diseases associated with NETosis), Nu.Q® Discover (nucleosome profiling), and Capture-PCR™/Capture-Seq™ (early cancer detection from plasma DNA).

• Operations span a 17,000 sq ft lab and 10,000 sq ft production facility in Belgium, an innovation lab in California, and offices in California, London, and Nevada, with approximately 72 employees.

• Collaborates with academic institutions, clinical centers, diagnostic and pharmaceutical companies, and financial institutions globally.

Financial performance and metrics

• Financial statements for years ended December 31, 2024 and 2023 are incorporated by reference, audited by Sadler, Gibb & Associates, LLC.

• Company has not generated significant revenue or achieved profitability and has a going concern opinion from auditors.

Use of proceeds and capital allocation

• Will not receive any proceeds from the sale of shares by selling stockholders; all proceeds go to the selling stockholders.

• Company pays registration-related expenses, while selling stockholders pay brokerage commissions and similar charges.